Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia

Phase 3 Completed 331 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia.

Timeline

Start: 2008-03
Primary completion: 2010-07
Completion: 2010-07

Publications

Chue P, Malla A, Bouchard RH, Lessard S, Ganesan S, Stip E, Johnson S, Chen E, Ahn YM, Kim YS, Robinson G, Schweikert C, Gendron A, Eriksson H; SPECTRUM XR Study Group. The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia. Curr Med Res Opin. 2013 Mar;29(3):227-39. doi: 10.1185/03007995.2012.762903. Epub 2013 Jan 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Quetiapine	Small molecule	400 mg	—
Subject	Quetiapine	Small molecule	800 mg	—

Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia

Summary

Timeline

Publications

Drugs

Indications